CD8A and neoplasm: This cross-reactivity of microbes with tumor antigens influences anti-cancer immunotherapy as well, as CD4+ and CD8+ T cells specific for microbial epitopes are necessary for the efficacy of anti-PD1 and anti-CTLA4 therapies (128, 138).